Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion type Assertion NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_head.
- NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion description "[Interestingly, 90% of patients with advanced stage cancer (stage IIIB/IV NSCLC or extensive SCLC) overexpressed HER-2/neu.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_provenance.
- NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion evidence source_evidence_literature NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_provenance.
- NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion SIO_000772 11679181 NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_provenance.
- NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion wasDerivedFrom befree-20150227 NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_provenance.
- NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_assertion wasGeneratedBy ECO_0000203 NP380541.RAhZj4cl5zBqCimW64ty26UNzu7h1LPpWlCPCpWfmXxPg130_provenance.